Vertaling van "osteoporosis in postmenopausal women " (Frans → Nederlands) :

Guidelines for the diagnosis and manegement of osteoporosis in postmenopausal women and men from the age of 50 years in the UK.
Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK.

Gauthier K, Bai A, Perras C et al ; Canadian Agency for Drugs and Technologies in Health. Denosumab, raloxifene, and zoledronic acid for the treatment of postmenopausal osteoporosis : clinical effectiveness and harms.
postmenopausal osteoporosis : clinical effectiveness and harms.

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
Once-yearly zoledronic acid for treatment of postmenopausal osteoporis.

Bon à savoir: traitement de substitution hormonale et risque de cancer du sein invasif. Folia Pharmacotherapeutica 2011; 38:4-5. [http ...]
Anderson GL, Limacher M, Assaf AR et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.

Arch Intern Med 2006; 166:357-65. Vickers MR, MacLennan AH, Lawton B et al. Main morbidities recorded in the women’s international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women.
Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial.

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy : the Women’s Health Initiative randomized controlled trial.
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial.

Risks and benefits of estrogen plus progestin in healthy postmenopausal women : principal results From the Women’s Health Initiative randomized controlled trial.
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial.

L’enquête constitue la pierre angulaire d’une nouvelle campagne lancée aujourd’hui par l’International Osteoporosis Foundation (IOF) et la Medical Women’s International Association (MWIA), qui vise à remettre en question les stéréotypes dépassés et à informer les femmes sur la réalité de l’ostéoporose.
De enquête vormt de hoeksteen van een nieuwe campagne die vandaag wordt gelanceerd door de International Osteoporosis Foundation (IOF) en de Medical Women’s International Association (MWIA), met de bedoeling de achterhaalde vooroordelen in vraag te stellen en vrouwen een beter inzicht te geven in osteoporose.